Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By Region & Competition, 2021-2031F

The Global Losartan market is anticipated to expand from USD 743.21 million in 2025 to USD 933.37 million by 2031, reflecting a compound annual growth rate (CAGR) of 3.87%. As an angiotensin II receptor blocker (ARB), Losartan is a key pharmaceutical treatment for hypertension and associated cardiovascular issues like diabetic nephropathy. Market expansion is primarily driven by a rising worldwide incidence of high blood pressure and a growing elderly population, which collectively broaden the patient base in need of ongoing pharmacological care. The World Health Organization's 2025 Global Hypertension Report noted that roughly 1.4 billion individuals had hypertension in 2024, highlighting an immense and escalating need for reliable antihypertensive medications. Furthermore, increased emphasis on early detection and sustained management of high blood pressure continues to stimulate market development.

A major obstacle to market growth is the fierce competition among generic drug manufacturers and the relentless pressure on pricing. Because Losartan is a broadly accessible generic drug, it continuously competes against other ARBs and various categories of blood pressure medications. This intense rivalry, paired with widespread initiatives to curb healthcare costs, forces pharmaceutical prices downward and subsequently restricts opportunities for revenue growth within the sector.

Market Driver

The rising worldwide incidence of hypertension is a core driver for the global Losartan market, directly increasing the number of patients who need reliable antihypertensive therapies. High blood pressure affects a massive segment of adults globally, creating a continuous need for pharmacological solutions like Losartan. The World Health Organization highlighted in its 2025 Global Hypertension Report, published on September 23, 2025, that uncontrolled high blood pressure causes more than 10 million deaths annually, revealing a steady necessity for proven and accessible treatments. This widespread health issue ensures stable prescription volumes and emphasizes Losartan's essential function in reducing cardiovascular dangers.

At the same time, the global surge in the elderly population plays a major role in driving the Losartan market forward. Seniors face a naturally higher risk of hypertension and related cardiovascular conditions, which drives up the demand for long-term medication management. Data from the World Health Organization on October 1, 2025, projects that the global demographic of people aged 60 and older will grow from 1.1 billion in 2023 to 1.4 billion by 2030, creating a vast group in need of sustained medical care. Because of its proven effectiveness and broad availability, Losartan is well-positioned to serve this expanding patient demographic. Additionally, the widespread presence of generic Losartan options improves both affordability and market access. The 2025 U.S. Generic & Biosimilar Medicines Savings Report, published on September 3, 2025, by the Association for Accessible Medicines and the Biosimilars Council, revealed that generic and biosimilar drugs saved patients and the U.S. healthcare system $467 billion in 2024, underscoring the financial advantages and increasing utilization of these treatments.

Market Challenge

The Global Losartan industry encounters substantial hurdles due to severe generic rivalry and persistent pricing constraints. Being a readily accessible generic angiotensin II receptor blocker, Losartan is in continuous competition with a variety of other generic blood pressure medications, encompassing alternative ARBs and distinct therapeutic categories. This intensely contested landscape, combined with widespread global efforts to control healthcare expenditures, places intense downward pressure on drug prices. Consequently, this environment severely restricts the capacity for revenue growth among Losartan producers.

The economic consequences of this rivalry are deeply felt throughout the generic pharmaceutical industry. The Association for Accessible Medicines (AAM) noted in its 2025 U.S. Generic & Biosimilar Medicines Savings Report that while generic and biosimilar drugs made up 90 percent of all dispensed prescriptions in 2024, they represented only 12 percent of total prescription expenditures. This stark contrast highlights the intense pricing limitations within the generic market, leading directly to reduced profit margins and hindered growth for specific generic therapies such as Losartan. The relentless push for more affordable alternatives drives down revenue per unit, effectively capping total market valuation even when prescription rates remain high.

Market Trends

A major trend shaping the global Losartan market is the creation of innovative drug formulations that improve both patient adherence and medication accessibility. These advancements cater to distinct patient requirements, especially for those who struggle to swallow conventional solid pills. For instance, launching ready-to-use liquid versions of Losartan simplifies the dosing process for children, the elderly, and patients with dysphagia, eliminating the varied quality and complications often linked to compounded drugs. A commercial update from Scienture Holdings, Inc. on February 3, 2026, highlighted that the firm increased U.S. availability of Arbli(TM), the initial FDA-cleared ready-to-use oral liquid Losartan, to over 2,500 healthcare facilities via Institutional GPO contracts, showcasing a dedicated push to expand market penetration and elevate patient care.

Additionally, the growing range of clinical uses for Losartan outside of its core hypertension focus marks another significant market trend. Although widely recognized for regulating blood pressure, continuous studies and updated clinical protocols are increasingly highlighting its effectiveness in treating other renal and cardiovascular ailments, including diabetic nephropathy and heart failure. This expanding medical utility establishes Losartan as an adaptable treatment capable of delivering multiple advantages, such as vital organ protection and better health outcomes in complicated medical situations. A study featured in the American Heart Association Journals on September 4, 2025, titled 'Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multidatabase Target Trial Emulation Studies,' revealed that the five-year cumulative rate of all-cause mortality for patients starting on ARBs was 3.04%, which is significantly lower than the 3.45% seen in patients starting ACE inhibitors, further validating the robust protective benefits of ARBs across wider clinical applications.

Key Market Players

• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis International AG
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Ltd.
• Torrent Pharmaceutical Ltd.
• Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source

• Contract Manufacturing Organizations
• In-House

Losartan Market, By Application

• Hypertension
• Stroke
• Diabetic Nephropathy
• Others

Losartan Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations:

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).